podis-shutterstock-com-biologics-
PODIS / Shutterstock.com
8 September 2016AsiaAlan Adcock and Atthachai Homhuan

A bright future for biologics in Thailand

In 2002, the Thai government initiated a universal scheme to bring equitable healthcare access to the general public. Under the scheme, hospitals receive per capita funding based on 47 million people. At the outset, funding was approximately $38 per person; now, it is $83. Although per capita funding has more than doubled, the current figure is still low. This budget constraint has led the Thai government to favour generic companies as opposed to originator companies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
27 May 2026   China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.
Asia
20 May 2026   Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives.
Asia
31 March 2026   The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.